First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

奥西默替尼 医学 内科学 肺癌 肿瘤科 四分位间距 临床终点 表皮生长因子受体 临床研究阶段 无进展生存期 置信区间 胃肠病学 外科 癌症 临床试验 化疗 埃罗替尼
作者
Margarita Majem,Ivanna Sullivan,Santiago Viteri,Guillermo López-Vivanco,Manuel Cobo,José Miguel Sánchez,Jorge García,J. Garde,Miguel Sampayo,Griselda Martrat,Andrea Malfettone,Niki Karachaliou,Miguel Ángel Molina‐Vila,Rafael Rosell
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:159: 174-181 被引量:7
标识
DOI:10.1016/j.ejca.2021.09.039
摘要

The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met.In this multicentre, single-arm, open-label, phase IIa study, patients with locally advanced or metastatic NSCLC harbouring centrally confirmedEGFR Thr790Met mutation received 80 mg osimertinib daily. The primary end-point was objective response rate (ORR). The secondary end-points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. Efficacy was assessed as per Response Evaluation Criteria in Solid Tumours, version 1.1. Blood samples collected at baseline, end of week 2 and disease progression were analysed using next-generation sequencing. As osimertinib was approved as a first-line therapy during the trial, this led to early termination of phase II; thus, analysis is considered exploratory.Twenty-two patients were enrolled and received osimertinib. All 22 patients were included in the efficacy and safety analysis. At the data cutoff, 10 (50%) patients remained on treatment. The median duration of follow-up was 24.4 months (interquartile range 12.9 to 26.0). The ORR was 77.3% (17/22 [95% confidence interval {CI} 54.6 to 89.3]). The DCR was 86.4% (19/22, [95% CI 65.1 to 97.1]). The median PFS was 23.1 months (95% CI 14.1 to NE). The median OS was 28·4 months (95% CI 25.6 to NE).Despite early study termination, osimertinib first-line therapy yields an overall PFS of 23.1 months in EGFR-mutant patients harbouring a coexisting low allelic fraction of EGFR Thr790Met mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
css1997完成签到 ,获得积分10
1秒前
无限飞丹完成签到,获得积分10
1秒前
小饭完成签到,获得积分10
1秒前
Cl1audia发布了新的文献求助10
2秒前
所所应助木可采纳,获得10
2秒前
Gyro完成签到,获得积分10
4秒前
隐形曼青应助lzx采纳,获得10
4秒前
5秒前
体贴紫完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
五六七完成签到,获得积分10
7秒前
7秒前
liz_发布了新的文献求助10
8秒前
新xin发布了新的文献求助10
9秒前
CodeCraft应助111111111采纳,获得10
10秒前
汉堡包应助秋天里的水采纳,获得10
11秒前
量子星尘发布了新的文献求助10
11秒前
Gyro发布了新的文献求助50
11秒前
慕青应助keyun采纳,获得10
11秒前
体贴紫发布了新的文献求助10
11秒前
12秒前
Dr.Who发布了新的文献求助10
13秒前
14秒前
深情安青应助科研通管家采纳,获得10
14秒前
彭于晏应助科研通管家采纳,获得10
14秒前
搜集达人应助科研通管家采纳,获得10
14秒前
顾矜应助科研通管家采纳,获得10
14秒前
华仔应助科研通管家采纳,获得10
14秒前
Owen应助科研通管家采纳,获得10
14秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
赘婿应助科研通管家采纳,获得10
15秒前
Ava应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
Owen应助科研通管家采纳,获得10
15秒前
桐桐应助科研通管家采纳,获得10
15秒前
dali完成签到 ,获得积分10
16秒前
accept发布了新的文献求助10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174